---
title: "What Elevance Health Holders Got Right"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306380588.md"
description: "Elevance Health shares rose 25.1% over the past year, defying concerns about Medicaid pressure and CMS audits. Investors benefited from raised 2026 EPS guidance and improving net margins (2.3% to 2.7%), validating bullish narratives centered on AI-driven cost controls and Carelon's stability. At $394, the stock remains below the $370 fair value estimate, with analysts highlighting HealthOS and Sydney Health tools as key drivers for predictable earnings."
datetime: "2026-11-22T02:15:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306380588.md)
  - [en](https://longbridge.com/en/news/306380588.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306380588.md)
generator: "portal-rs"
---

# What Elevance Health Holders Got Right

If you only skimmed the headlines about Elevance Health wrestling with Medicaid pressure, CMS audits, and lawsuits, this outcome might surprise you. Investors who held Elevance Health over the past year are up 25.1%, including dividends. That gain arrived alongside both margin worries and guidance raises as fresh quarterly results landed through 2026. If you were weighing the stock back in November 2025 with only those early ACA and Medicaid concerns on record, what exactly were you being paid to bear?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

This theme extends beyond Elevance Health. See which of 35 healthcare AI stocks may still merit a closer look.

## The Two Stories Elevance Health Investors Had To Choose Between

The shares cost US$314 at the start of the period, and Elevance Health sat between two very different but reasonable stories about where earnings power might settle.

The bullish case, with a Fair Value of US$370, assumed revenue growth of 6.8%, profit margin rising to 3.2%, and a future P/E of 12.5x. It leaned on analytics and AI to trim administrative costs and on Carelon and value-based care to support more stable margins.

The bearish narrative put Fair Value at US$297 and focused on ACA and Medicaid pressure. It highlighted elevated medical cost trends, slow Medicaid rate realignment, and provider use of AI for aggressive coding as risks that could compress margins even if technology helped operations.

## What The Results Changed For Elevance Health

Elevance Health lifted 2026 adjusted EPS guidance after Q1 and Q2 results and then raised it again following a Q3 2026 beat, which leaned toward the bullish margin recovery story. Across the period, revenue moved from US$50,711m in Q3 2025 to US$51,429m in Q3 2026 and net income increased, while net margin shifted from 2.3% to 2.7%, softening the bear case but not settling it.

The key assumption on trial was whether margins in government backed plans could recover. For any other insurer with similar debates, track the reported benefit or net margin each quarter and compare it with management guidance to see whether pricing and cost controls are actually holding.

## What Elevance Health's Run Now Prices In

With Elevance Health at US$394, the bullish analyst Narrative on Simply Wall St still places its Fair Value above the current share price rather than at or below it.

The Narrative leans on Elevance Health’s Carelon and AI tooling as levers for steadier government margins that investors today may not fully credit.

> *"HealthOS and Sydney Health are already shortening the time it takes Elevance Health to spot emerging cost patterns, and wider use of these tools to automate prior authorization and tighten billing integrity could shift earnings quality by reducing surprise movements in the benefit expense ratio and supporting more predictable net margins."*

One Narrative disagrees with today's price. **→ See where this Narrative says Elevance Health should trade**

## Find Your Own Contrarian Opportunity

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

-   Company 1 - 29% below our estimate - uses expanded manufacturing lines and owned distribution to emphasize higher-margin specialty films and services.
-   Company 2 - 48% below our estimate - scales digital loan origination workflows and integrated business accounts to strengthen core small enterprise relationships.
-   Company 3 - 40% below our estimate - converts contracted solar and storage backlog into grid-modernization projects that replace aging transmission assets.

Three companies from the same screener. Open **every one of the 40 undervalued companies on it →**

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [What Elevance Health (ELV)'s Medicaid Margin Recovery Plan Means For Shareholders](https://longbridge.com/en/news/305922488.md)
- [Elevance Health Director Ramiro G. Peru Reports Acquisition of $383,860 in Common Shares](https://longbridge.com/en/news/306285611.md)
- [Elevance Health (ELV) Raises Earnings Outlook Following Fair Value Gap Comes Into Focus](https://longbridge.com/en/news/305294781.md)
- [This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday](https://longbridge.com/en/news/306003889.md)
- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**